Vor-Wordmark-RGB-FullColor-070920.png
Vor Reports Second Quarter 2021 Financial Results and Provides Company Update
August 09, 2021 16:05 ET | Vor Biopharma
On track to report initial VOR33 clinical data in the first half of 2022Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignanciesInitiated...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
July 08, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs
June 17, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company) announced today that it will build-out an in-house clinical manufacturing facility in Cambridge,...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp
June 11, 2021 08:00 ET | Vor Biopharma
Mr. Patterson brings nearly 30 years of senior leadership experience in biotechnology, including leading Audentes Therapeutics from inception through acquisition over an eight-year periodKush M....
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Develop Multi-Targeted CAR-Ts with Abound Bio
June 10, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass. and PITTSBURGH, June 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) and Abound Bio today announced they have entered into a multi-year strategic collaboration and license...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences
May 25, 2021 16:10 ET | Vor Biopharma
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Reports First Quarter 2021 Financial Results and Provides Company Update
May 06, 2021 16:08 ET | Vor Biopharma
Health Canada clears the CTA for VOR33 clinical trial Vor to present on VOR33 manufacturing scale-up and in-depth genomic characterization at the American Society of Gene & Cell Therapy (ASGCT)...
Vor-Wordmark-RGB-FullColor-070920.png
Vor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT
April 28, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) is pleased to announce that Vor scientists will give two presentations documenting the development, manufacturing,...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Reports Fiscal Year 2020 Financial Results
March 25, 2021 16:35 ET | Vor Biopharma
IND accepted for VOR33, Vor’s lead eHSC product candidate for treatment of AML Completed initial public offering raising $203.4 million in total gross proceeds CAMBRIDGE, Mass.,...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Biopharma to Present at the Barclays Global Healthcare Conference
March 05, 2021 15:00 ET | Vor Biopharma
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted...